Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2812988 | 0.89 | SMN1; SMN2 (0.45) | SMN1; SMN2POLBKDM4EMAPTALDH1A1 | |
| SCHEMBL17957235 | 0.82 | CA12 (0.41) | SMN1; SMN2POLBMAPTALDH1A1KMT2A | |
| SCHEMBL13133008 | 0.81 | NTRK1 (0.50) | SMN1; SMN2POLBKDM4EMAPTALDH1A1 | |
| SCHEMBL17957293 | 0.81 | CA12 (0.44) | SMN1; SMN2POLBMAPTALDH1A1HPGD | |
| SCHEMBL17957303 | 0.81 | ALDH1A1 (0.41) | SMN1; SMN2POLBKDM4EMAPTALDH1A1 | |
| SCHEMBL17957271 | 0.80 | RAB9A (0.44) | SMN1; SMN2POLBKDM4EMAPTALDH1A1 | |
| SCHEMBL2816165 | 0.80 | COPS5 (0.43) | SMN1; SMN2POLBMAPTALDH1A1HPGD | |
| SCHEMBL13133006 | 0.79 | KDR (0.44) | SMN1; SMN2POLBMAPTALDH1A1RAB9A | |
| SCHEMBL13133018 | 0.79 | HPSE (0.44) | SMN1; SMN2POLBKMT2AMEN1RAB9A | |
| SCHEMBL13170180 | 0.79 | CA12 (0.42) | SMN1; SMN2MAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2193122-B1 | IMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-08-03 | — | — | EP | claimed |
| US-20100249132-A1 | IMIDAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-30 | — | — | US | claimed |
| EP-2193122-B1 | IMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249132-A1 | IMIDAZOLE DERIVATIVES | SDHA, SDHB, TPD52L2 | SMN1; SMN2 3994/4885POLB 2686/4885KDM4E 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.